INC Research Acquires Leading Australian CRO Trident Clinical Research
INC Research, LLC announced the acquisition of Trident Clinical Research to expand its clinical trials outsourcing footprint and expertise in Australia, New Zealand, and India. Under the terms of the agreement, Trident will become a wholly owned affiliate of INC Research and will operate as Trident Clinical Research, an INC Research company through its offices in Sydney, Brisbane, Melbourne, Adelaide, Auckland, and Mumbai. Trident’s operation in Mumbai will increase the reach of INC Research’s clinical and data operations located in Gurgaon, India.
“Trident is an important piece in our strategy to build a sustainable CRO business that both satisfies and anticipates the global drug development needs of our customers,” said James Ogle, CEO of INC Research.
Founded in 1997, Trident has strategically grown to become one of Australia’s larges CROs with more than 100 employees across three countries, a full range of clinical research services, and diverse therapeutic experience. Trident has more than 500 clinical studies completed across Phase I to IV, including over 100 Phase I studies.
Based on data from the Economist Intelligence Unit, Australia offers significant cost advantages, has a highly efficient regulatory system according to timeline indicators and is a desirable location to conduct early phase clinical trials, especially when compared to the USA, UK, Germany, Japan and Singapore. Australia achieves very rapid study timelines without the need for IND or CTA. For these reasons, Australia is becoming a prime destination for conducting first-in-man and early phase clinical studies.
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Patient Engagement Platform Checklist
November 22nd 2024Modern clinical trials are more complex than ever, and one significant reason is the increased focus on patient engagement. Incorporating a patient engagement platform into your clinical trial enhances the patient experience and can lead to more successful trials with stronger, more reliable outcomes. We put together this helpful checklist of key features to look out for when choosing a platform for your study.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
